Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generium Pharmaceutical
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
- Contract Manufacturing Organization
- Generic Drugs
- Other Names / Subsidiaries
- International Biotechnology Center (IBC) Generium, Generium JSC, AO Generium